文献速递炎症性肠病

克罗恩病停用抗TNF后复发预测:个体参与者数据荟萃分析

Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-04-30

该研究纳入14项研究、11个国家、1317例克罗恩病患者,验证STORI预测模型并构建更新模型。停用抗TNF后中位13个月复发632例,1年汇总复发率38%。STORI模型区分度差(C统计量0.51),更新模型区分度中等(C统计量0.59),加粪钙卫蛋白后提升至0.63。

要点

  • 停用抗TNF后1年汇总复发率为38%,中位复发时间13个月。
  • STORI模型区分度差(C统计量0.51),更新模型中等(0.59)。
  • 更新模型纳入临床症状、发病年龄、免疫抑制剂、吸烟等因素。

核心结论

  • 更新预测模型区分度中等(C统计量0.59),优于既往STORI模型(0.51),经进一步验证后可能有助于指导克罗恩病停用抗TNF的临床决策。

研究设计与样本

  • 个体参与者数据荟萃分析,纳入14项研究、11个国家、1317例缓解期克罗恩病患者,抗TNF治疗时长至少6个月。
  • 验证STORI模型区分度(C统计量)与校准度,并构建更新预后模型,通过交叉验证评估性能。

主要发现

  • 停用抗TNF后632/1317例复发,中位复发时间13个月,1年汇总复发率38%。
  • STORI模型区分度差(C统计量0.51);更新模型区分度中等(C统计量0.59)。
  • 更新模型纳入停用时临床症状(HR 2.2;95%CI 1.2-4)、诊断年龄较小(A1 vs A2 HR 1.5;95%CI 1.11-1.89)、未联用免疫抑制剂(HR 1.4;95%CI 1.18-172)、吸烟(HR 1.4;95%CI 1.15-1.67)、二线抗TNF(HR 1.3;95%CI 1.01-1.69)、上消化道受累(L4 vs 非L4 HR 1.3;95%CI 0.96-1.79)、阿达木单抗(vs 英夫利西单抗 HR 1.22;95%CI 0.99-1.50)、停用年龄(每年轻10岁 HR 1.2;95%CI 1-1.33)、C反应蛋白(每倍增 HR 1.04;95%CI 1.00-1.08)、较长病程(每5年 HR 1.07;95%CI 0.98-1.17)。
  • 亚组分析中,加入粪钙卫蛋白后模型区分度提升(C统计量0.63)。

临床怎么用

  • 更新模型可用于评估克罗恩病缓解期停用抗TNF后的复发风险,辅助临床决策,但需进一步验证。

局限性

  • 更新模型区分度仅为中等(C统计量0.59),预测性能有限。
  • 研究结论需进一步外部验证后方可用于临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Tools for stratification of relapse risk of Crohn's disease (CD) after anti-tumor necrosis factor (TNF) therapy cessation are needed. We aimed to validate a previously developed prediction model from the diSconTinuation in CrOhn's disease patients in stable Remission on combined therapy with Immunosuppressants (STORI) trial, and to develop an updated model. METHODS: Cohort studies were selected that reported on anti-TNF cessation in 30 or more CD patients in remission. Individual participant data were requested for luminal CD patients and anti-TNF treatment duration of 6 months or longer. The discriminative ability (concordance-statistic [C-statistic]) and calibration (agreement between observed and predicted risks) were explored for the STORI model. Next, an updated prognostic model was constructed, with performance assessment by cross-validation. RESULTS: This individual participant data meta-analysis included 1317 patients from 14 studies in 11 countries. Relapses after anti-TNF cessation occurred in 632 of 1317 patients after a median of 13 months. The pooled 1-year relapse rate was 38%. The STORI prediction model showed poor discriminative ability (C-statistic, 0.51). The updated model reached a moderate discriminative ability (C-statistic, 0.59), and included clinical symptoms at cessation (hazard ratio [HR], 2.2; 95% CI, 1.2-4), younger age at diagnosis (HR, 1.5 for A1 (age at diagnosis ≤16 years) vs A2 (age at diagnosis 17 - 40 years); 95% CI, 1.11-1.89), no concomitant immunosuppressants (HR, 1.4; 95% CI, 1.18-172), smoking (HR, 1.4; 95% CI, 1.15-1.67), second line anti-TNF (HR, 1.3; 95% CI, 1.01-1.69), upper gastrointestinal tract involvement (HR, 1.3 for L4 vs non-L4; 95% CI, 0.96-1.79), adalimumab (HR, 1.22 vs infliximab; 95% CI, 0.99-1.50), age at cessation (HR, 1.2 per 10 years younger; 95% CI, 1-1.33), C-reactive protein (HR, 1.04 per doubling; 95% CI, 1.00-1.08), and longer disease duration (HR, 1.07 per 5 years; 95% CI, 0.98-1.17). In subanalysis, the discriminative ability of the model improved by adding fecal calprotectin (C-statistic, 0.63). CONCLUSIONS: This updated prediction model showed a reasonable discriminative ability, exceeding the performance of a previously published model. It might be useful to guide clinical decisions on anti-TNF therapy cessation in CD patients after further validation.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Pauwels RWM, van der Woude CJ, Nieboer D, et al. Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. Clin Gastroenterol Hepatol. 2021. PMID: 33933376. doi:10.1016/j.cgh.2021.03.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。